RBC Capital analyst Shagun Singh lowered the firm’s price target on Edwards Lifesciences to $105 from $118 and keeps an Outperform rating on the shares. Edwards is hosting an investor conference on Thursday, December 8, and plans to discuss its innovation strategy, and product pipeline, as well as provide a financial outlook for 2023. Singh expects focus on trends in U.S. TAVR volumes and expectations around staffing, U.S. Pascal ramp, and the impact of FX to the P&L, the analyst tells investors in a research note.
Published first on TheFly
Read More on EW: